The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1372
September 5, 2011
View Complete Issue         Table of Contents 2019 
Gabapentin Enacarbil (Horizant) for Restless Legs Syndrome
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Gabapentin Enacarbil (Horizant) for Restless Legs Syndrome
September 5, 2011 (Issue: 1372)
Gabapentin enacarbil (Horizant – GlaxoSmithKline), a new extended-release (ER) tablet formulation of gabapentin, has been approved by the FDA for treatment of moderate-to-severe restless legs syndrome (RLS). The immediate-release (IR)...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Gabapentin Enacarbil (Horizant) for Restless Legs Syndrome
Article code: 1372b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.